Unipath attempts to disguise redundancies in UK
This article was originally published in Clinica
Unipath, a subsidiary of the Anglo-Dutch Unilever, a publicly-owned company, is in the process of reducing its workforce by a quarter. The company made the decision in June of this year to make redundant some 150 of its 550-strong UK staff, with cuts across the board in management and non-management positions. Unipath said the cuts were necessary because sales of its contraceptive device, Persona, had not taken off as the company expected.
You may also be interested in...
The run-away US FDA advisory committee review of Biogen’s Alzheimer’s candidate was highly unusual. But like most things at the agency, not entirely unprecedented.
Trump Administration’s attempt to eliminate rebates in the US Medicare outpatient drug benefit program is the easiest and most certain item among the 11th hour pricing policy changes for the incoming Biden Administration to undo. But it still had a major impact on the dynamics of the drug pricing debate.
US FDA will simultaneously review the vaccines, with Moderna’s advisory committee set a week after Pfizer’s. ACIP emergency meeting scheduled for 1 December with vote likely on distribution priority for health care personnel.